Successful Therapy of Advanced Arteriosclerosis Obliterans With Prostacyclin

Szczeklik, Andrzej; Skawiński, S; Głuszko, Piotr; Niżankowski, Rafał; Szczeklik, J; Gryglewski, Ryszard J.

doi:10.1016/s0140-6736(79)91792-6

Cited by 262 publications

(54 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, quite a few patients are unsuitable for operation. Despite technical progress, the treatment of patients with inoperable chronic CLI is still challenging; most of the patients have to undergo amputation: [6][7][8][9] 33% at 6 months and 51% at 2 years. [10] SCS has been recommended to treat ischemic pain and prevent amputation in patients with inoperable CLI.…”

Section: Introductionmentioning

confidence: 99%

Spinal cord stimulation for patients with inoperable chronic critical leg ischemia

Chen

2011

World Journal of Emergency Medicine

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Spinal cord stimulation for patients with inoperable chronic critical leg ischemia

Chen

2011

World Journal of Emergency Medicine

View full text Add to dashboard Cite

“…Biological actions of prostacylin include inhibition of platelet aggregation and adhesion, inhibition of vascular smooth muscle tone and growth, inhibition of leukocyte activation and adhesion, and reduction of cholesteryl ester accumulation in cells of the vessel wall (14). These biological actions of prostacyclin and its efficacy in the treatment of complications of atherosclerosis such as peripheral vascular disease (15,16) suggest that prostacylin is an endogenous antiatherogenic molecule.…”

Section: Introductionmentioning

confidence: 99%

Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine.

Zembowicz

Jones²,

1995

J. Clin. Invest.

View full text Add to dashboard Cite

Lysophosphatidyicholine (lysoPC), a component of atherogenic lipoproteins and atherosclerotic lesions, has been recently suggested to play a role in atherogenesis. LysoPC is known to induce several endothelial genes involved in leukocyte recruitment, mitogenesis, and inflammation. Cyclooxygenases (prostaglandin H2 synthases) are rate-limiting enzymes involved in the endothelial synthesis of prostacyclin, an antiplatelet, vasorelaxant, and vasoprotective molecule. We investigated the effect of lysoPC on the endothelial expression of cyclooxygenases. Our results demonstrate that, in cultured human umbilical vein endothelial cells, lysoPC induces cyclooxygenase-2 mRNA and protein levels. Increased expression of cyclooxygenase-2 is accompanied by the enhancement of both basal-and calcium ionophore A23187-induced synthesis of prostacyclin. Nuclear runoff experiments demonstrated an increased rate of transcription of the cyclooxygenase-2 gene by lysoPC. In contrast, lysoPC did not affect the expression of constitutive cyclooxygenase-1. Our results suggest that the induction of endothelial cyclooxygenase-2 by lysoPC may be an important vasoprotective mechanism that limits progression of atherosclerotic lesions and promotes their regression. (J.

show abstract

“…4,5 The first report of a therapeutic response to prostaglandin E 1 (PGE 1 ) in limb ischemia described the responses of five patients with advanced arteriosclerosis obliterans of the lower extremities; improvement was seen in all of the patients. 6 Numerous subsequent studies have been performed. The results of 12 long-term, randomized, open or double-blind trials to compare intra-arterial or intravenous infusions of either PGE 1 , ciprostene, or iloprost with placebo, in patients with advanced chronic limb ischemia, were summarized in 1991.…”

Section: Discussionmentioning

confidence: 99%

Treprostinil for the treatment of severe digital necrosis in systemic sclerosis

Engel

Rockson

2005

Vasc Med

View full text Add to dashboard Cite

Abstract:We report a case of severe digital ulcerations associated with systemic sclerosis, successfully treated with treprostinil (Remodulin ® ). There was improvement within days of the treatment initiation; complete healing was accomplished after 16 weeks of therapy. Patients with systemic sclerosis and peripheral small vessel disease have limited therapeutic options. Treprostinil is a prostacyclin analogue that can be delivered by subcutaneous infusion and is approved in the USA only for treatment of primary pulmonary hypertension. This report provides an impressive example of an alternative, complementary indication for the use of treprostinil.

show abstract

Successful Therapy of Advanced Arteriosclerosis Obliterans With Prostacyclin

Cited by 262 publications

References 17 publications

Spinal cord stimulation for patients with inoperable chronic critical leg ischemia

Spinal cord stimulation for patients with inoperable chronic critical leg ischemia

Induction of cyclooxygenase-2 in human umbilical vein endothelial cells by lysophosphatidylcholine.

Treprostinil for the treatment of severe digital necrosis in systemic sclerosis

Contact Info

Product

Resources

About